In recent blog posts and video updates, I indicated my increasing bullishness about Cue Biopharma (CUE). And this morning, we learned it’s completely justified.
So much so, in fact, I’m convinced this is the last call to load up the truck with shares before the rest of Wall Street figures it out.
Because forget being “poised to deliver a major breakthrough in immunotherapy,” as I’ve previously predicted. Cue Biopharma (CUE) just did!
Moments ago, the company announced paradigm-shifting, platform-validating patient data from its ongoing monotherapy trial for CUE-101 in HPV cancers.
This is definitive proof, based upon industry-accepted evaluation criteria, known as RECIST, that CUE-101 is selectively targeting, activating and impacting disease progression for patients.
Newsflash: That’s something that’s never been done before in immunotherapies. So analysts can longer downplay the data for CUE-101, as they’ve been doing for months now.
For example, in mid-March, the analyst at BTIG insisted we shouldn’t “expect to see true RECIST responses” until we got data from the combo trail with Merck & Co.’s (MRK) Keytruda.
Try again, friend!
Before he, along with the other overly skeptical sell-side lemmings actually try again and “revise” their outlooks, here are five key takeaways every investor should know before loading up on shares, which could ultimately be worth $150+ as more data is reported, and strategic interest heats up…
(And yes, I’m aware that projection represents more than 10x upside from here. But I’m not crazy. It’s backed up by recent deals in the biotech space, as you’ll see in a moment).